DrugCards

Home
Estonia
Tallinn
DrugCards

AI-powered pharmacovigilance automation for global and local literature monitoring and regulatory intelligence

DrugCard is an Estonian technology company specializing in pharmacovigilance automation. The company develops an AI-powered platform for automated medical literature screening, regulatory intelligence, and drug safety monitoring. DrugCard covers 121+ countries and monitors over 2,200 local journals not indexed in global databases such as PubMed, reducing literature screening time by up to 70% comp

ared to manual processes. The platform serves pharmaceutical companies, contract research organizations (CROs), and marketing authorization holders (MAHs). In addition to its software, DrugCard offers managed pharmacovigilance services including local and global literature screening, case processing, signal detection, and regulatory writing. Founded in 2021 and headquartered in Tallinn, Estonia, the company has grown to 30 employees and serves clients across Europe, the Middle East, and Asia.

08/09/2026

🇳🇱 Meet DrugCard at World Patient Safety Congress (formerly World Drug Safety Congress) Europe 2026!

We’re excited to join one of Europe’s key events, bringing together leaders in patient safety, pharmacovigilance, risk management, AI, and automation.
Our team attending in Amsterdam:

👤 Dmytro Horilyk — Co-Founder & CEO
👤 Artem Horilyk — Co-Founder & CPO
👤 Christina Kiselova — Head of Sales & Partnerships
👤 Diana Budkevych — Head of Marketing
👤 Olha Lysiuk — Head of PV Department
👤 Anastasiia Shapovalova — Key Account Manager
👤 Karyna Shevchuk — HR Manager / Executive Assistant

And you’ll find us at Booth 507! 🚀

We’re looking forward to meeting PV and patient safety professionals, sharing experiences, talking about AI and automation, and hearing what challenges teams are facing today.

📍 RAI Amsterdam | Booth 507
📅 22–24 September 2026

Coming to the congress? Come say hello - we’d love to meet you! 👋

04/09/2026

The demo is over. The recording is now available. 🎥

Yesterday, we had a great discussion about what really happens when a pharmacovigilance team selects and implements a computerised system.

And the feedback showed us that these are exactly the topics PV professionals are thinking about.

A few takeaways from our participants:
💬 “Choosing and implementing a computerised system is much more than evaluating a product during a demo.”
💬 “The practical points on vendor assessment, system implementation, user onboarding, integrations, upgrades, revalidation and audit readiness were particularly valuable.”
💬 “I especially appreciated the real-life examples and discussion of challenges that companies actually face when selecting, implementing and maintaining computerized systems.”

Thank you to everyone who joined Dmytro Horilyk and Jan Kolouch for the discussion and shared their feedback.

Couldn’t join us live? The full recording is now available.
🎥 Watch the webinar: https://youtu.be/NiI7RIE15-s?si=SZ8tdNfcNOmspZZd

01/09/2026

💊𝗢𝗳𝗳-𝗟𝗮𝗯𝗲𝗹 𝗨𝘀𝗲 𝗜𝘀 𝗮 𝗣𝗩 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗧𝗼𝗼
A recent finding in 📚 literature monitoring brought us back to an important PV topic: 🚦 off-label drug use.
DrugCard identified an MHRA Drug Safety Update on 💉botulinum toxin type A, highlighting updated warnings about the risk of iatrogenic botulism, including risks associated with use outside licensed indications.
❓It raised a familiar question: 𝙬𝙝𝙖𝙩 𝙙𝙤𝙚𝙨 𝙤𝙛𝙛-𝙡𝙖𝙗𝙚𝙡 𝙪𝙨𝙚 𝙢𝙚𝙖𝙣 𝙛𝙤𝙧 𝙥𝙝𝙖𝙧𝙢𝙖𝙘𝙤𝙫𝙞𝙜𝙞𝙡𝙖𝙣𝙘𝙚 𝙩𝙚𝙖𝙢𝙨?
👉 Read our new article: https://drug-card.io/blog/off-label-drug-use-ema-safety-monitoring-and-reporting-requirements/

26/08/2026

🎙️ Webinar: What the Demo Doesn't Show

Anyone who's chosen or implemented a computerised system in pharmacovigilance knows the drill: the demo always looks perfect. Then reality kicks in — data migration, integrations, upgrades, audits...

On September 3rd, we're bringing together two people who've been through it more than once:

👤 Jan Kolouch — CEO & Co-Founder of Next PV Services, EU QPPV, Strategic PV Advisor. 5 years of choosing, implementing, and maintaining various computerised systems.
👤 Dmytro Horilyk — CEO at DrugCard

What we'll cover:
✅ How to choose the right vendor and solution for your business case
✅ What to look for beyond the demo, so the system actually fits your real-world processes
✅ Data migration — plan for it early, not after the fact
✅ Integrations, maintenance, and upgrades — build them into your budget from day one
✅ What auditors expect from computerised systems, and how to be audit-ready before go-live

📅 September 3, 2026
🕐 15:00 CEST
🌐 Online, free participation

Register here: https://drugcards-26507628.hubspotpagebuilder.eu/en/what-the-demo-doesnt-show?utm_source=facebook&utm_medium=organic_social&utm_campaign=what_the_demo_doesnt_show&utm_content=facebook_page

25/08/2026

𝗧𝗵𝗲 𝗥𝗲𝗮𝗰𝘁𝗶𝗼𝗻 𝗛𝗮𝗽𝗽𝗲𝗻𝗲𝗱. 𝗧𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 𝗗𝗶𝗱𝗻’𝘁. 𝗪𝗵𝘆?
Why do healthcare professionals 📑underreport adverse drug reactions?
👨🏻‍⚕️They’re busy. They’re uncertain. The reporting process can be complicated. And sometimes, they don’t see what happens after they click “submit.”
🧩In our new blog post, we explore what’s behind ADR underreporting — from workload and causality uncertainty to fragmented reporting processes and lack of feedback.
Because better ADR reporting is ultimately about quality, not just quantity.
👉 Read the new article: https://drug-card.io/blog/underreporting-of-adverse-drug-reactions-why-healthcare-professionals-don-t-report/

18/08/2026

𝟱 𝗟𝗶𝘁𝗲𝗿𝗮𝘁𝘂𝗿𝗲 𝗠𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗣𝗩 𝗧𝗲𝗮𝗺𝘀 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗶𝗻 𝟮𝟬𝟮𝟲📚
Choosing literature monitoring software may seem simple until you start comparing options.
Finding 📑publications is only one part of the process. The real challenge is identifying relevant safety information, detecting potential ICSRs, covering local and non-indexed literature, documenting decisions, and maintaining an audit-ready workflow.
𝙎𝙤, 𝙬𝙝𝙖𝙩 𝙙𝙤𝙚𝙨 𝙩𝙝𝙚 𝙗𝙚𝙨𝙩 𝙡𝙞𝙩𝙚𝙧𝙖𝙩𝙪𝙧𝙚 𝙢𝙤𝙣𝙞𝙩𝙤𝙧𝙞𝙣𝙜 𝙨𝙤𝙛𝙩𝙬𝙖𝙧𝙚 𝙡𝙤𝙤𝙠 𝙡𝙞𝙠𝙚 𝙞𝙣 2026?
We compared 5️⃣ solutions for pharmacovigilance literature monitoring, looking at:

🔎 Global and local literature coverage
🤖 AI-assisted screening and article categorisation
📋 ICSR detection
🌍 Multilingual and non-indexed sources
🔐 Audit trails and traceability
⚙️ Automation and PV workflow integration

And the answer isn't simply "the tool with the most features." It's about finding the right fit for your PV workflow.

👉 Read the new blog post: https://drug-card.io/blog/5-best-literature-monitoring-software-for-pharmacovigilance/

11/08/2026

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝗶𝘁 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝘁𝗮𝗸𝗲 𝘁𝗼 𝗯𝗲𝗰𝗼𝗺𝗲 𝗮 𝘁𝗿𝘂𝘀𝘁𝗲𝗱 𝗣𝗩 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹?
It’s not just about knowing the regulations.
In pharmacovigilance, trust matters most when data is incomplete, timelines are tight, and decisions are not straightforward.
🎤In our latest interview, Erika Barbarosie, Associate Director, PV Compliance at Gilead Sciences, shares a practical perspective on what builds trust in real-world PV work — from working with regulators and escalating safety concerns to using AI without losing the human judgement behind critical decisions.

💡One takeaway stood out:
𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐜𝐚𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐚 𝐏𝐕 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧. 𝐈𝐭 𝐜𝐚𝐧𝐧𝐨𝐭 𝐭𝐚𝐤𝐞 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐟𝐨𝐫 𝐢𝐭.

👉Read the full interview and discover what trust looks like when patient safety is on the line: https://drug-card.io/blog/how-pharmacovigilance-experts-build-trust-with-regulators-partners-and-internal-teams/

04/08/2026

𝗠𝗼𝘀𝘁 𝗮𝗱𝘃𝗲𝗿𝘀𝗲 𝗲𝘃𝗲𝗻𝘁𝘀 𝗮𝗿𝗲𝗻'𝘁 𝗯𝗹𝗮𝗰𝗸-𝗮𝗻𝗱-𝘄𝗵𝗶𝘁𝗲.
Two experienced pharmacovigilance professionals can review the same case and reach different conclusions. Why?
🧩Causality assessment is one of the few areas in pharmacovigilance where uncertainty is expected. Real-world safety cases rarely come with complete timelines, perfect documentation, or a single obvious explanation.
Instead, safety professionals must answer one difficult question:
𝘿𝙞𝙙 𝙩𝙝𝙚 𝙢𝙚𝙙𝙞𝙘𝙞𝙣𝙚 𝙖𝙘𝙩𝙪𝙖𝙡𝙡𝙮 𝙘𝙖𝙪𝙨𝙚 𝙩𝙝𝙚 𝙖𝙙𝙫𝙚𝙧𝙨𝙚 𝙚𝙫𝙚𝙣𝙩 - 𝙤𝙧 𝙬𝙖𝙨 𝙞𝙩 𝙟𝙪𝙨𝙩 𝙖 𝙘𝙤𝙞𝙣𝙘𝙞𝙙𝙚𝙣𝙘𝙚?

🔥In our latest blog, we explore how causality assessment works in everyday pharmacovigilance, the methods safety teams use, the challenges they face, and why expert medical judgment remains essential - even as AI becomes part of the workflow.
👨🏻‍💻If you've ever struggled with an incomplete ICSR or debated whether a case should be classified as "possible" or "probable," this article is for you.
👉Read it here: https://drug-card.io/blog/causality-assessment-in-pharmacovigilance-practical-challenges-for-safety-teams/

03/08/2026

Our co-founder and CEO, Дмитро Горілик, recently sat down with Founder Story to talk about how DrugCard actually came to be.

It goes back to 2019, when literature monitoring (one of the most critical, and most manual, parts of pharmacovigilance) kept raising the same question for co-founder Artem Horilyk: why is this still done by hand?

That question turned into an MVP in 2020, a market launch in 2021, and a lot of hard lessons since - including Dmytro learning to sell a technical product with zero sales background, by walking into customer offices and just asking questions.

The interview also covers:
→ Early hiring mistakes (and what they taught the team)
→ Betting on AI early - including a case intake process that went from 20 minutes to 90 seconds
→ Acquiring SIA OOM in Riga, DrugCard's first step toward becoming a pharmacovigilance infrastructure across Europe
→ Crossing $1M ARR and expanding to 138 countries

Read interview here: https://drug-card.io/news-updates/dmytro-horilyk-on-building-drugcard-founder-story/?utm_source=facebook&utm_medium=social&utm_campaign=2026q3_pr_global&utm_content=fb_drugcard

28/07/2026

📖𝗛𝗼𝘄 𝗺𝗮𝗻𝘆 𝗚𝗩𝗣 𝗺𝗼𝗱𝘂𝗹𝗲𝘀 𝗰𝗮𝗻 𝘆𝗼𝘂 𝗻𝗮𝗺𝗲 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘁𝗵𝗲𝗺 𝘂𝗽?
Most pharmacovigilance professionals know that Good Pharmacovigilance Practices (GVP) are the foundation of PV compliance. But when it comes to day-to-day work, some modules📙 have a much greater impact than others.
📌That's exactly what we explore in our latest blog - a practical overview of the active GVP modules, their purpose, and what they mean for MAHs and PV teams in everyday practice.
💡Whether you're refreshing your knowledge or onboarding new team members, this guide brings the GVP framework together in one place.
👉Read the full article: https://drug-card.io/blog/good-pharmacovigilance-practices-gvp-modules-explained-for-mahs-and-pv-teams/

𝙒𝙝𝙞𝙘𝙝 𝙂𝙑𝙋 𝙢𝙤𝙙𝙪𝙡𝙚 𝙝𝙖𝙨 𝙩𝙝𝙚 𝙗𝙞𝙜𝙜𝙚𝙨𝙩 𝙞𝙢𝙥𝙖𝙘𝙩 𝙤𝙣 𝙮𝙤𝙪𝙧 𝙙𝙖𝙞𝙡𝙮 𝙬𝙤𝙧𝙠?

Address

Tallinn

Website

https://drug-card.io/

Alerts

Be the first to know and let us send you an email when DrugCards posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DrugCards:

Want your practice to be the top-listed Clinic in Tallinn?